The results showed that TREM2f/f-Lyz2-Cre mice exhibited reduced tumor volumes and weights, slower tumor growth, and the combination therapy with the galectin-3 inhibitor GB1107 significantly decreased the tumor burden (Fig. 7B and D). The gene discussed is LGALS3; the disease is neoplasm.